Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients

T. Win, B.A. Thomas, T. Lambrou, B.F. Hutton, N.J. Screaton, J.C. Porter, T.M. Maher, R. Endozo, R.I. Shortman, A. Afaq, P. Lukey, P.J. Ell, A.M. Groves* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)


Patients with idiopathic pulmonary fibrosis (IPF) show increased PET signal at sites of morphological abnormality on high-resolution computed tomography (HRCT). The purpose of this investigation was to investigate the PET signal at sites of normal-appearing lung on HRCT in IPF.
Consecutive IPF patients (22 men, 3 women) were prospectively recruited. The patients underwent 18F-FDG PET/HRCT. The pulmonary imaging findings in the IPF patients were compared to the findings in a control population. Pulmonary uptake of 18F-FDG (mean SUV) was quantified at sites of morphologically normal parenchyma on HRCT. SUVs were also corrected for tissue fraction (TF). The mean SUV in IPF patients was compared with that in 25 controls (patients with lymphoma in remission or suspected paraneoplastic syndrome with normal PET/CT appearances).
The pulmonary SUV (mean ± SD) uncorrected for TF in the controls was 0.48 ± 0.14 and 0.78 ± 0.24 taken from normal lung regions in IPF patients (p < 0.001). The TF-corrected mean SUV in the controls was 2.24 ± 0.29 and 3.24 ± 0.84 in IPF patients (p < 0.001).
IPF patients have increased pulmonary uptake of 18F-FDG on PET in areas of lung with a normal morphological appearance on HRCT. This may have implications for determining disease mechanisms and treatment monitoring
Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number2
Early online date14 Aug 2013
Publication statusPublished - 2014

Bibliographical note

This work was undertaken at UCLH/UCL, which received a proportion of the funding from the UK’s Department of Health’s NIHR Biomedical Research Centre’s funding scheme.
Conflicts of interests
We acknowledge a proportion of funding and input from GSK (CRT115549) Research and Development in Stevenage, UK, and the GSK CRAFT consortium.

cited By 46


Dive into the research topics of 'Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients'. Together they form a unique fingerprint.

Cite this